Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1442 • ACR Convergence 2025
Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Ayumu Sugiura³, Jay Tang¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³, Paresh Thakker¹ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: As a chronic inflammatory disease, PsA is marked by cartilage and bone turnover and articular inflammation. Accordingly, elevated levels of inflammation and bone metabolism…
Abstract Number: 1261 • ACR Convergence 2025
Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA
Carter Pason¹, Sarah Hopkins Gillespie¹, Joelle Koplin², Rachael Hewitt³, Christine Bundy³, Ethan Craig⁴, Laura Coates⁵, Jessica A. Walsh⁶ and Alexis Ogdie⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Penn Medicine, Philadelphia, PA, ³University of Cardiff, Cardiff, United Kingdom, ⁴University of Pennsylvania, Wallingford, PA, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Approximately 60-70% of patients with PsA do not reach minimal disease activity (MDA) on therapy. However, in many cases, this may not be related…
Abstract Number: 0577 • ACR Convergence 2025
Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, mitsumasa kishimoto⁴, Ruben Queiro⁵, Ennio Lubrano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Enrique R. Soriano¹⁰, Proton Rahman¹¹, Frank Behrens¹² and Stefan Siebert¹³, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Kyorin University School of Medicine, Tokyo, Japan, ⁵Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ⁶Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹²Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ¹³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Randomized controlled trials have demonstrated the efficacy of IL-23 inhibitors (i) and IL-17i in PsA; however, real-world data on their effectiveness in heterogeneous patient…
Abstract Number: 0878 • ACR Convergence 2025
Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study
Maria Gabriella Raimondo¹, Hashem Mohammadian², Simon Rauber³, Stefano Alivernini⁴, Filippo Fagni⁵, Giulia Corte⁶, Koray Tascilar⁷, Alina Mihaela Ramming⁸, Juergen Rech², Maria Antonietta D´Agostino⁹, Georg Schett², Milena Pachowsky⁸, Arnd Kleyer¹⁰ and Andreas Ramming¹¹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ⁴Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁶- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Internal Medicine ³ – Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ¹⁰Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹¹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Enthesitis is an early event in the course of psoriatic arthritis (PsA) and a hallmark feature of the disease. Currently, much of the understanding…
Abstract Number: 0523 • ACR Convergence 2025
SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
Jennifer Soung¹, Virginie Kelly², Marni Wiseman³, Adrian Rodriguez⁴, Theodore Alkousakis⁵, Olivia Choi⁵, Daphne Chan⁵, Katelyn Rowland⁵, Linda Hou⁶, Jenny Jeyarajah⁷, Nastaran Abbarin⁸, Elizabeth Skobelev⁵, Sancharitha Ramji⁵, James Krell⁹, Max Sauder¹⁰ and David Adam¹¹, ¹Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ²Saint-Louis Medical Clinic, Quebec, Canada, Quebec, Canada, ³SkinWise Dermatology, Manitoba, Canada, Manitoba, Canada, ⁴Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA, Nashville, TN, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, ⁸Janssen Inc, Toronto, ON, Canada, Toronto, Canada, ⁹Total Skin & Beauty Dermatology Center, Birmingham, AL, USA, Birmingham, ¹⁰Probity Medical Research, ON, Canada; University of Toronto, ON, Canada, Toronto, Canada, ¹¹CCA Medical Research, ON, Canada, Toronto, Canada
Background/Purpose: Even low body surface area (BSA) psoriasis can be extremely bothersome to patients and can have a significant impact on their lives just as…
Abstract Number: 0108 • ACR Convergence 2025
In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis
Jesús Eduardo Martín Salazar¹, Clementina López Medina², Carlos Pérez Sánchez³, María Ángeles Puche-Larrubia⁴, Pedro Ortiz Buitrago⁵, María Dolores López-Montilla⁶, Iván Arias de la Rosa⁷, Laura Cuesta López⁸, Miriam Ruiz Ponce⁸, Antonio Barranco⁸, Laura Romero Zurita⁸, Elena Moreno-Caño⁹, Rafaela Ortega-Castro¹⁰, Jerusalén Calvo¹¹, M Carmen Abalos-Aguilera¹², Desiree Ruiz-Vilchez¹³, Chary López pedrera¹⁴, Alejandro Escudero Contreras¹¹, Eduardo Collantes estévez¹⁵ and Nuria Barbarroja¹⁶, ¹Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴Reina Sofia University Hospital, Granada, Spain, ⁵Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁶Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Córdoba, Spain, ⁹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹¹IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹³Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease for which TNFα inhibitors are the standard first-line biologic therapy. Nonetheless, a significant proportion of patients…
Abstract Number: 2690 • ACR Convergence 2025
Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Lihi Eder¹, Sohan Shahab², Sarah Hopkins Gillespie³, Laura Bumbulis⁴, Helen Emanoilidis⁵, Charlene Compher⁶, Jose Scher⁷, Dafna D. Gladman⁸, Richard Cook⁴, Vinod Chandran¹ and Alexis Ogdie⁹, ¹University of Toronto, Toronto, ON, Canada, ²Women’s College Research Institute, Women’s College Hospital, Toronto, Canada, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Waterloo, Waterloo, Canada, ⁵Women’s College Hospital, Toronto, Canada, ⁶University of Pennsylvania School of Nursing and Hospital of the University of Pennsylvania, Philadelphia, ⁷New York University School of Medicine, New York, NY, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: The Dietary Interventions in Psoriatic Arthritis (DIPSA) study is a multicentre randomized controlled trial (RCT) designed to evaluate the efficacy of two personalized dietary…
Abstract Number: 2367 • ACR Convergence 2025
Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Philip J. Mease¹, Andrew Ostor², Christopher Saffore³, Xiaolan Ye⁴, Manish Patel⁵, Ana Biljan⁶, Ralph Lippe⁵, Molly Edwards⁷, Iwan Armstrong⁷ and Xenofon Baraliakos⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Australian National University, Canberra, Australia, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Buffalo Grove, IL, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial involvement is a clinically relevant manifestation of psoriatic arthritis (PsA) that can influence management strategies. Evidence on the real-world effectiveness of advanced therapies,…
Abstract Number: 2332 • ACR Convergence 2025
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
Dafne capelusnik¹, Clementina López Medina², Désirée Van Der Heijde³, Daniel Aletaha⁴, Josef Smolen⁵, Anna Molto⁶ and Sofia Ramiro⁷, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁶Assistance Publique Hôpitauxde Paris, Paris, France, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Recent studies have highlighted the potential of composite scores such as the DAPSA for assessing peripheral arthritis in axSpA and pSpA. However, the swollen…
Abstract Number: 2036 • ACR Convergence 2025
JAK1 selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis
LETICIA LEON¹, Pedro Pablo Bermejo², Leonor Laredo³, José Alberto Peña⁴, María Teresa Benítez⁵, DALIFER FREITES⁶, CLARA DE MIGUEL³ and lydia Abasolo Alcazar⁷, ¹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ²Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ³Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁴Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Janus kinase inhibitors (JAKis) are effective therapeutic agents against chronic inflammatory arthritis (CIA). Tofacitinib and baricitinib were defined as pan-JAK inhibitors, while upadacitinib and…
Abstract Number: 1710 • ACR Convergence 2025
Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
Andre Lucas Ribeiro¹, Sibel Aydin², Gurjit Kaeley³, Fahmeen J. Afgani⁴, Catherine Bakewell⁵, Marcos Rosemffet⁶, Minna Kohler⁷, Amir Haddad⁸, Maria S. Stoenoiu⁹, Ari Polachek¹⁰, josefina marin¹¹, Arnon Katz¹², Sahil Koppikar¹³ and Lihi Eder¹⁴, ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³UF COM-J, Ponte Vedra Beach, FL, ⁴Women's College Hospital, Toronto, Canada, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁸Carmel Medical Centre, Haifa, Israel, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, ¹¹Hospital Universitario Rey Juan Carlos, Madrid, Spain, ¹²GRAPPA, Seattle, ¹³Women's College Hospital & University of Toronto, Markham, ON, Canada, ¹⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Enthesitis affects 30–40% of PsA patients but remains difficult to diagnose due to overlap with non-specific entheseal pain. While OMERACT has standardized ultrasound (US)…
Abstract Number: 1439 • ACR Convergence 2025
Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Vassiliki Poulia¹, Eleni Sampatakaki², Dimitrios Katsifis-Nezis³, Maria Pappa³, Evangelia Mole⁴, Sousana Gazi⁴, Elpida Skouvaklidou⁵, Nikolaos Kougkas⁵, Maria Polyzou⁶, Loukia Koutsogeorgopoulou⁶, Ioannis Xynogalas⁷, Anastasios Karamanakos⁷, Konstantinos D Vassilakis¹, Evangelos Papadimitriou⁸, Charalampos Papagoras⁸, Gerasimos Evangelatos⁹, Nafsika Gerolymatou¹⁰, Paraskevi V Voulgari¹⁰ and George E Fragoulis¹, ¹First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ²Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ³Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁴Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁵⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ⁶Department of Pathophysiology, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁷Department of Rheumatology, Evangelismos General Hospital, Athens, Attiki, Greece, ⁸First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece, ⁹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Bimekizumab, a dual IL-17 A and F blocker, has recently been added in the therapeutic rheumatologist’s armamentarium of PsA, but real-world evidence is lacking.…
Abstract Number: 1241 • ACR Convergence 2025
Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life
Kyra Chen¹, Uma Scher² and Rebecca Haberman³, ¹NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ²NYU School of Medicine, Scarsdale, NY, ³NYU Langone Health, New York, NY
Background/Purpose: Pain remains a major burden in psoriatic arthritis (PsA), often persisting despite effective control of synovial inflammation. This persistent pain may prevent patients from…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 0877 • ACR Convergence 2025
Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
Rodrigo García Salinas¹, Gisel Reyes-Jara², Felicia Almada³, Juan Arguello² and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano de La Plata, La Plara, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The transition from psoriasis (Pso) to psoriatic arthritis (PsA) presents an opportunity for early intervention and preventive strategies in high-risk patients with arthralgia. Objectives:…

« Previous Page
1
…
3
4
5
6
7
…
93
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].